[1] |
Redman CW, Sargent IL. Latest advances in understanding preeclampsia[J]. Science, 2005, 308(5728):1592-1594.
|
[2] |
Sibai B, Dekker G, Kupferminc M. Pre-eclampsia[J]. Lancet, 2005, 365(9461):785-799.
|
[3] |
The preeclampsia foundation. Preeclampsia foundation annual report 2006[J/OL]. [2014-12-25].
URL
|
[4] |
Staff AC, Dechend R, Redman CW. Review: Preeclampsia, acute atherosis of the spiral arteries and future cardiovascular disease: two new hypotheses[J]. Placenta, 2013, 34 Suppl:S73-S78.
|
[5] |
Maul H, Longo M, Saade GR, et al. Nitric oxide and its role during pregnancy: from ovulation to delivery[J]. Curr Pharm Des, 2003, 9(5): 359-380.
|
[6] |
Staff AC, Dechend R, Pijnenborg R. Learning from the placenta: acute atherosis and vascular remodeling in preeclampsia-novel aspects for atherosclerosis and future cardiovascular health[J]. Hypertension, 2010, 56(6):1026-1034.
|
[7] |
Redman CW, Sargent IL. Immunology of pre-eclampsia[J]. Am J Reprod Immunol, 2010, 63(6):534-543.
|
[8] |
Schiessl B, Strasburger C, Bidlingmaier M, et al. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intrauterine growth restricted and preeclamptic pregnancies[J]. Arch Gynecol Obstet, 2006, 274(3):150-154.
|
[9] |
Mao D, Che J, Li K, et al. Association of homocysteine, asymmetric dimethylarginine, and nitric oxide with preeclampsia[J]. Arch Gynecol Obstet, 2010, 282(4): 371-375.
|
[10] |
González-Garrido Chem JA, Olivares-Corichi IM, Tovar-Rodriguez JM, et al. Influence of the AT(2) receptor on the L-arginine-nitric oxide pathway and effects of (-)-epicatechin on HUVECs from women with preeclampsia[J]. J Hum Hypertens, 2013, 27(6):355-361.
|
[11] |
Matsubara K, Matsubara Y, Hyodo S, et al. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia[J]. J Obstet Gynaecol Res, 2010, 36(2):239-247.
|
[12] |
Khalil AA, Tsikas D, Akolekar R, et al. Asymmetric dimethylarginine, arginine and homoarginine at 11-13 weeks′ gestation and preeclampsia: a case-control study[J]. Hum Hypertens, 2013, 27(1):38-43.
|
[13] |
Rizos D, Eleftheriades M, Batakis E, et al. Levels of asymmetric dimethylarginine throughout normal pregnancy and in pregnancies complicated withpreeclampsia or had a small for gestational age baby[J]. J Matern Fetal Neonatal Med, 2012, 25(8):1311-1315.
|
[14] |
Sandrim VC, Palei AC, Metzger IF, et al. Interethnic differences in ADMA concentrations and negative association with nitric oxide formation in preeclampsia[J]. Clin Chim Acta, 2010, 411(19-20):1457-1460.
|
[15] |
Krause BJ, Hanson MA, Casanello P. Role of nitric oxide in placental vascular development and function[J]. Placenta, 2011, 32(11):797-805.
|
[16] |
Baylis C, Beinder E, Süt T, et al. Recent insights into the roles of nitric oxide and renin-angiotensin in the pathophysiology of preeclamptic pregnancy[J]. Semin Nephrol, 1998, 18(2):208-230.
|
[17] |
Martin D, Conrad KP. Expression of endothelial nitric oxide synthase by extravillous trophoblast cells in the human placenta[J]. Placenta, 2000, 21(1): 23-31.
|
[18] |
Bamberger AM, Koglin M, Kempfert J, et al. Expression and tissue localization of soluble guanylyl cyclase in the human placenta using novel antibodies directed against the alpha(2) subunit[J]. J Clin Endocrinol Metab, 2001, 86(2): 909-912.
|
[19] |
Al-Hijji J, Andolf E, Laurini R, et al. Nitric oxide synthase activity in human trophoblast, term placenta and pregnant myometrium[J]. Reprod Biol Endocrinol, 2003, 1:51.
|
[20] |
Poniedziaek-Czajkowska E, Marciniak B, Kimber-Trojnar Z, et al. Nitric oxide in normal and preeclamptic pregnancy[J]. Curr Pharm Biotechnol, 2011 12(5):743-749.
|
[21] |
Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice[J]. Nature, 1995, 376(6535):62-66.
|
[22] |
George EM, Granger JP. Endothelin: key mediator ofhypertension in preeclampsia[J]. Am J Hypertens, 2011, 24(9):964-969.
|
[23] |
Chen Q, Chen L, Liu B, et al. The role of autocrine TGFbeta1 in endothelial cell activation induced by phagocytosis of necrotic trophoblasts: a possible role in the pathogenesis of pre-eclampsia[J]. J Pathol, 2010, 221(1):87-95.
|
[24] |
Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012[J]. J Pregnancy, 2012; 2012:586578.
|
[25] |
Perlik M, Seremak-Mrozikiewicz A, Barlik M, et al. Genetic variants of endothelial nitric synthase in gestational hypertension and preeclampsia[J]. Ginekol Pol, 2012, 83(9): 652-659.
|
[26] |
Johal T, Lees CC, Everett TR, et al. The nitric oxide pathway and possible therapeutic options in pre-eclampsia[J]. J Clin Pharmacol, 2014, 78(2):244-257.
|
[27] |
Luzi G, Caserta G, Iammarino G, et al. Nitric oxide donors in pregnancy: fetomaternal hemodynamic effects induced in mild pre-eclampsia and threatened preterm labor[J]. Ultrasound Obstet Gynecol, 1999, 14(2):101-109.
|
[28] |
Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis[J]. Circulation, 2002, 106(19): 2510-2513.
|
[29] |
Bath PM, Pathansali R, Iddenden R, et al. The effect of transdermal glyceryl trinitrate, a nitric oxide donor, on blood pressure and platelet function in acute stroke[J]. Cerebrovasc Dis, 2001, 11(3): 265-272.
|
[30] |
Facchinetti F, Longo M, Piccinini F, et al. L-arginine infusion reduces blood pressure in preeclamptic women through nitric oxide release[J]. J Soc Gynecol Investig, 1999, 6(4): 202-207.
|
[31] |
Vadillo-Ortega F, Perichart-Perera O, Espino S, et al. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomized controlled trial[J]. BMJ, 2011, 342: d2901.
|
[32] |
Samangaya RA, Mires G, Shennan A, et al. A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia[J]. Hypertens Pregnancy, 2009, 28(4):369-382.
|
[33] |
Ramesar SV, Mackraj I, Gathiram P, et al. Sildenafil citrate decreases sFlt-1 and sEng in pregnant l-NAME treated Sprague-Dawley rats[J]. Eur J Obstet Gynecol Reprod Biol, 2011, 157(2): 136-140.
|
[34] |
Herraiz S, Pellicer B, Serra V, et al. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats[J]. BJOG, 2012, 119(11):1394-1402.
|
[35] |
Green LS, Chun LE, Patton AK, et al. Mechanism of inhibition for N6022, a first-in-class drug targeting S-nitrosoglutathione reductase[J]. Biochemistry, 2012, 51(10): 2157-2168.
|
[36] |
Chen Q, Sievers RE, Varga M, et al. Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats in vivo[J]. J Appl Physiol, 2013, 114(6):752-760.
|
[37] |
Colagiovanni DB, Drolet DW, Langlois-Forget E, et al. A nonclinical safety and pharmacokinetic evaluation of N6022: a first-in-class S-nitrosoglutathione reductase inhibitor for the treatment of asthma[J]. Regul Toxicol Pharmacol, 2012, 62(1): 115-124.
|